Patients with rheumatoid arthritis who received sarilumab plus a DMARD who did not respond to anti-TNF medications showed statistically significant and clinically meaningful changes from baseline in fatigue, morning stiffness, pain, productivity, and participation at week 24.
The US Food and Drug Administration (FDA) has approved Belbuca (buprenorphine) buccal film (developed by Endo Pharmaceuticals and BioDelivery Sciences) for treating chronic pain in patients for whom existing alternatives don’t work.
Canadian researchers suggest that quality-controlled herbal cannabis, if used by cannabis-experienced patients as part of a monitored treatment program over one year, appears to be reasonably safe for the treatment of chronic pain.
On the battlefield soldiers can suffer any number of injuries that can lead to a lifetime of painful injuries. How doctors approach that care can affect the quality of life their patients enjoy long after their time in the service is done.
Like every year, PAINWeek, which kicks off this week in Las Vegas, will include dozens of presentations on abuse and diversion. It is a topic that is always front and center for pain management practitioners, and one for which there are no easy answers.